Fight Against Cancer Innovation Trust

Fight Against Cancer Innovation Trust

FACIT was established by the Ontario Institute for Cancer Research to commercialize cancer-related intellectual property emerging from Ontario's academic and hospital networks. Its mandate is translational: identify high-potential oncology innovations, fund their earliest development stages, and structure stand-alone companies that can attract follow-on venture financing. The firm operates as a commercialization venture partner rather than a passive grant-maker, embedding itself in portfolio companies to provide executive management and strategic guidance. The firm pursues a full continuum of capital deployment covering seed, start-up, growth, and later-stage venture rounds across biotechnology and health diagnostics. Its portfolio spans therapeutic, device, and diagnostic companies — many originating from Ontario's university and hospital ecosystem. FACIT uses direct equity investments alongside its structured funds, notably the Prospects Fund for early-stage validation, Compass Rose for later-stage growth, and the WeSEED program targeting early seed. It participates in co-investment alongside institutional and angel networks, often syndicating rounds to attract private capital to the province's oncology pipeline. FACIT reports 29 first-in-human studies and multiple Ontario start-ups created, with active employment maintained within the province. The firm's team size is not publicly disclosed, and no additional offices have been noted beyond its Toronto headquarters. In April 2026, NerView Surgical won the $100,000 Ernsting Entrepreneurship award at FACIT's annual Falcons' Fortunes pitch competition, underscoring the firm's continued role in advancing surgical oncology ventures. The firm has also formalized a strategic network with the Ontario Centre of Innovation in late 2025 to strengthen commercialization support for emerging life-science companies. FACIT's structural differentiator is its public-origin, translational mandate. Unlike a standard venture firm, it stewards a pipeline fed directly by the Ontario Institute for Cancer Research and the provincial government, which funds part of its operations. This creates a province-anchored investment filter: FACIT selects projects for local economic impact as much as financial return, keeping intellectual property, teams, and company headquarters in Ontario. The governance relationship with OICR embeds a public-interest requirement that shapes its portfolio construction and exit timing.